Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Marotti

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Breast Cancer Research and Treatment|December 11, 2014
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancerJennifer R Bean, Sarah R Hosford, Lynn K Symonds, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylationSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast CancerNicole A Traphagen, Gary N Schwartz, Steven Tau, et al.
British Journal of Cancer|October 27, 2021
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancerYaileen D Guzmán-Arocho, Shoshana M Rosenberg, Judy E Garber, et al.
Cancer Research|January 8, 2025
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast CancerSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Breast Cancer Research and Treatment|June 21, 2020
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancerMary D Chamberlin, Jason D Wells, Kevin Shee, et al.
The Oncologist|July 25, 2015
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterLaura J Tafe, Ivan P Gorlov, Francine B de Abreu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2020
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast CancerMargaret L Axelrod, Mellissa J Nixon, Paula I Gonzalez-Ericsson, et al.
Cancer Research|December 4, 2016
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear PolaritySarah Chiang, Britta Weigelt, Huei-Chi Wen, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Breast Cancer Research and Treatment|December 11, 2014
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancerJennifer R Bean, Sarah R Hosford, Lynn K Symonds, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylationSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast CancerNicole A Traphagen, Gary N Schwartz, Steven Tau, et al.
British Journal of Cancer|October 27, 2021
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancerYaileen D Guzmán-Arocho, Shoshana M Rosenberg, Judy E Garber, et al.
Cancer Research|January 8, 2025
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast CancerSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Breast Cancer Research and Treatment|June 21, 2020
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancerMary D Chamberlin, Jason D Wells, Kevin Shee, et al.
The Oncologist|July 25, 2015
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterLaura J Tafe, Ivan P Gorlov, Francine B de Abreu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2020
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast CancerMargaret L Axelrod, Mellissa J Nixon, Paula I Gonzalez-Ericsson, et al.
Cancer Research|December 4, 2016
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear PolaritySarah Chiang, Britta Weigelt, Huei-Chi Wen, et al.
Pageof 7